Dicerna Pharmaceuticals (DRNA)

Executive Summary

Dicerna Pharmaceuticals was a biotechnology company focused on RNAi therapeutics using its proprietary GalXC™ platform to silence disease-driving genes in the liver. The company's pipeline targeted rare, cardiometabolic, and chronic liver diseases, with its lead candidate nedosiran for primary hyperoxaluria. In December 2021, Dicerna was acquired by Novo Nordisk and is now a wholly-owned subsidiary, integrating its RNAi technology into Novo Nordisk's R&D. This acquisition ended Dicerna's public trading and shifted its focus to supporting Novo Nordisk's pipeline, particularly in areas like cardiometabolic diseases and chronic hepatitis B. As a subsidiary, Dicerna's operations are now part of a larger organization with significant resources. The GalXC platform remains a key asset for developing subcutaneously administered RNAi therapies. While nedosiran is the most advanced program, Novo Nordisk is likely advancing it through regulatory processes and exploring other indications. The integration may have accelerated development timelines, but the company no longer reports independently, making it challenging to assess progress. Overall, Dicerna's technology is now embedded in Novo Nordisk's strategy, with potential for future value if programs succeed.

Upcoming Catalysts (preview)

• Q2 2024Nedosiran Regulatory Decision in Primary Hyperoxaluria (US/EU)75% success
• Q4 2024Phase 2 Data for RNAi Therapy in Cardiovascular Disease60% success
• Q3 2024Update on GalXC Platform Partnership Expansion50% success